Lida Pacaud

IGI Technologies (United States) — United States

Medicine · Health Sciences

24h-index8.8kcitations134works2.52yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

CAR-T cell therapy research(89), Multiple Myeloma Research and Treatments(63), Biosimilars and Bioanalytical Methods(29), Protein Degradation and Inhibitors(25), Lymphoma Diagnosis and Treatment(14)

Publications134 total

554 Pharmacokinetics (PK) and pharmacodynamics (PD) of ISB 2001, a BCMAxCD38xCD3 trispecific antibody, in TRIgnite-1, the first-in-human (FIH) phase 1 study in relapsed/refractory multiple myeloma (RRMM)
Regular and Young Investigator Award Abstracts·2025Open Access
TRIgnite- 1Study, Phase 1, First-in-Human Study of ISB 2001: A BCMAxCD38xCD3-Targeting Trispecific Antibody for Patients with Relapsed/Refractory Multiple Myeloma (RRMM)—Dose Escalation (DE) Results
Clinical Lymphoma Myeloma & Leukemia·2025· 1 cited
Phase 1, first-in-human study of ISB 2001: A BCMAxCD38xCD3-targeting trispecific antibody for patients with relapsed/refractory multiple myeloma (RRMM)—Dose escalation (DE) results.
Journal of Clinical Oncology·2025· 4 cited
Abstract CT147: Pharmacokinetics (PK) and pharmacodynamics (PD) of ISB 2001, a novel BCMAxCD38xCD3 trispecific antibody from the first-in-human (FIH) phase 1 study in relapsed/refractory multiple myeloma patients
Cancer Research·2025
Abstract 3694: Clinical validation of a quantitative systems pharmacology (QSP) model of ISB 2001 used for deriving first in human (FIH) dose and efficient phase 1 dose escalation design in relapsed refractory multiple myeloma (RRMM) patients
Cancer Research·2025· 1 cited
Characteristics and outcomes in patients with lenalidomide-refractory multiple myeloma treated with 1-3 prior lines of therapy: Analysis of individual patient-level data from daratumumab clinical trials
European Journal of Cancer·2024· 6 cited
First Results of a Phase 1, First-in-Human, Dose Escalation Study of ISB 2001, a BCMAxCD38xCD3 Targeting Trispecific Antibody in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)
Blood·2024· 8 citedOpen Access
ISB 2001: Accelerating Patient Benefits through Quantitative Systems Pharmacology (QSP) Guided First-in-Human (FIH) Starting Dose Selection
Blood·2024Open Access
Dose Escalation of ISB 1442, a Novel CD38 Biparatopic x CD47 Bispecific Antibody, in Patients with Relapsed / Refractory Multiple Myeloma
Blood·2024· 1 citedOpen Access
Progression-free survival as a surrogate endpoint for overall survival in patients with relapsed or refractory multiple myeloma
BMC Cancer·2024· 6 citedOpen Access
Abstract 1238: ISB 2001, a BCMA and CD38 dual targeting T cell engager, demonstrates superior cytotoxicity relative to teclistamab in the samples of patient relapsing from CD38 and BCMA targeted immunotherapies
Cancer Research·2024
Characterization and Outcomes of Spanish Patients With Relapsed/Refractory Multiple Myeloma Included in the LocoMMotion Study
Clinical Lymphoma Myeloma & Leukemia·2023· 1 cited
A Phase 1, First-in-Human, Dose Escalation and Dose-Expansion Study of a BCMAxCD38xCD3 Targeting Trispecific Antibody ISB 2001 in Subjects with Relapsed/Refractory Multiple Myeloma
Blood·2023· 4 cited
Integrated Preclinical Data Analysis of ISB 2001 Enables Optimal Starting Dose Selection for a First-in-Class Trispecific T Cell Engager Phase1 Study in Multiple Myeloma
Blood·2023· 1 citedOpen Access
Dose Escalation of ISB 1342, a Novel CD38xCD3 Bispecific Antibody, in Patients with Relapsed / Refractory Multiple Myeloma (RRMM)
Blood·2023· 9 cited
Initial Dose Escalation of ISB 1442, a Novel CD38 Biparatopic x CD47 Bispecific Antibody, in Patients with Relapsed / Refractory Multiple Myeloma (RRMM)
Blood·2023· 6 citedOpen Access
702 Phase 1 study of DLL3-directed chimeric antigen receptor T-cells in subjects with extensive stage small cell lung cancer
Regular and Young Investigator Award Abstracts·2023· 4 citedOpen Access
OA-47 Additional analysis of CARTITUDE-4: Cilta-cel vs standard of care (PVd or DPd) in lenalidomide-refractory patients with multiple myeloma and 1–3 prior lines of therapy
Clinical Lymphoma Myeloma & Leukemia·2023· 1 cited
P-275 CARTITUDE-1 final results: phase 1b/2 study of ciltacabtagene autoleucel in heavily pretreated patients with relapsed/refractory multiple myeloma
Clinical Lymphoma Myeloma & Leukemia·2023· 3 cited
POSTER: MM-309 CARTITUDE-1 Final Results: Phase 1b/2 Study of Ciltacabtagene Autoleucel in Heavily Pretreated Patients With Relapsed/Refractory Multiple Myeloma
Clinical Lymphoma Myeloma & Leukemia·2023· 2 cited
page 1 of 7Next →

Frequent Co-authors

Jordan M. Schecter(19), Carolyn C. Jackson(15), Enrique Zudaire(12), Tzu‐Min Yeh(12), Adam D. Cohen(12), William Deraedt(12), Deepu Madduri(12), Stephen J. Schuster(11), Edmund K. Waller(11), Peter Borchmann(11), Joseph P. McGuirk(11), Samantha Jaglowski(11), Saad Z. Usmani(11), Michael Bishop(10), Isabelle Fleury(10), Gilles Salles(10), Richard T. Maziarz(10), Jesús G. Berdeja(10), Mounzer Agha(10), Andrzej Jakubowiak(10)